180
Participants
Start Date
March 3, 2015
Primary Completion Date
May 22, 2018
Study Completion Date
September 20, 2020
NBTXR3
One intratumor implantation by injection
Radiation therapy
5 weeks/50 Gy (5 x 2 Gy by week)
Capital Region Cancer Service, Canberra Hospital, Canberra
Chris O'Brien Lifehouse, Sydney
Jules Bordet Institute, Brussels
Ghent University Hospital, Ghent
Centre Rene Gauducheau, Nantes
Institut Bergonie, Bordeaux
Centre Leon Berard, Lyon
Institut Paoli Calmettes, Marseille
Centre Regional de Lutte Contre Le Cancer Paul Lamarque, Montpellier
Centre Antoine Lacassagne, Nice
Institut Curie, Paris
Institut Claudius Regaud - Oncopole, Toulouse
Institut Gustave Roussy, Villejuif
Klinikum Mannheim, Mannheim
Klinikum Nürnberg, Nuremberg
Princes of Wales Hospital, Shatin
Medical Centre, Hungarian Defence Forces, Budapest
National Institute of Oncology, Budapest
University Pècs, Pécs
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Institute of Oncology Veneto IOV, Padua
Instituto Nazionale Tumori Regina Elena, Rome
Oslo University Hospital, Oslo
Perpetual Succour Hospital Cebu, Cebu City
University of Santo Thomas, Manila
The Medical City, Pasig
St. Luke's Medical Center, Quezon City
Cancer Center Institute, Warsaw
Institutul Oncologic Bucuresti, Bucharest
Spitalului Universitar de Urgenta Militar Central, Bucharest
Amethyst-Cluj, Floreşti
County Hospital 'Dr Gavril Curteanu', Oradea
County Hospital, Targu Mures, Târgu Mureş
Municipal Emergency Hospital, Timișoara
Iatros International, Bloemfontein
The Oncology Centre, Durban
Gvi Outeniqua Oncology Unit, George
Wilgers Oncology Centre, Pretoria
Hospital Universitari Vall D'Hebron, Barcelona
Hospital Clinico Universitario San Carlos, Madrid
START MADRID, Hospital Fundacion Jimenez Diaz, Madrid
START MADRID, Hospital Universitario Madrid Norte Sanchinarro, Madrid
Lead Sponsor
Collaborators (1)
PharmaEngine
INDUSTRY
Nanobiotix
INDUSTRY